Loading
PARP3 (Protein mono-ADP-ribosyltransferase PARP3) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer and Prostate cancer.
Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins and plays a key role in the response to DNA damage. Mediates mono-ADP-ribosylation of glutamate, aspartate or lysine residues on target proteins. In contrast to PARP1 and PARP2, it is not able to mediate poly-ADP-ribosylation.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.92, genetic association 0.00, clinical 0.98).
In plain words · PARP3 (Protein mono-ADP-ribosyltransferase PARP3) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer and Prostate cancer.
PARP3 (Protein mono-ADP-ribosyltransferase PARP3) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer and Prostate cancer.
Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins and plays a key role in the response to DNA damage. Mediates mono-ADP-ribosylation of glutamate, aspartate or lysine residues on target proteins.
No product in this corpus aims at PARP3 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PARP3: RNA low tissue specificity; high antibody staining in 13 normal tissues; highest cancer staining head and neck cancer (2 of 4 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Ovarian cancer, Prostate cancer); Open Targets associates it with 4 specific cancer types at or above 0.5 (ovarian cancer, ovarian carcinoma, fallopian tube cancer, primary peritoneal carcinoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PARP3 tissue; Open Targets ENSG00000041880 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Koch-Nolte, 1998. Source.
Sources: HGNC HGNC:273 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9Y6F1 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000041880 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: prostate cancer 0.51, ovarian cancer 0.59 (GraphQL API, CC0))
Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins and plays a key role in the response to DNA damage. Mediates mono-ADP-ribosylation of glutamate, aspartate or lysine residues on target proteins. In contrast to PARP1 and PARP2, it is not able to mediate poly-ADP-ribosylation. Involved in DNA repair by mediating mono-ADP-ribosylation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism, such as histone H2B, XRCC5 and XRCC6. ADP-ribosylation follows DNA damage and appears as an obligatory step in a detection/signalling pathway leading to the reparation of DNA strand breaks. Involved in single-strand break repair by catalysing mono-ADP-ribosylation of histone H2B on 'Glu-2' (H2BE2ADPr) of nucleosomes containing nicked DNA. Location: Nucleus; Chromosome; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole (UniProt). Locus 3p21.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Breast, Bronchus, Caudate, Cervix, Colon.
Medium only: breast cancer, carcinoid, endometrial cancer, liver cancer.
HPA PARP3 tissue · HPA PARP3 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PARP3" OR ABSTRACT:"PARP3" OR TITLE:"poly ADP-ribose polymerase family member 3" OR ABSTRACT:"poly ADP-ribose polymerase family member 3" OR TITLE:"Protein mono-ADP-ribosyltransferase PARP3" OR ABSTRACT:"Protein mono-ADP-ribosyltransferase PARP3" OR TITLE:"ADPRT3" OR ABSTRACT:"ADPRT3" OR TITLE:"IRT1" OR ABSTRACT:"IRT1" OR TITLE:"hPARP-3" OR ABSTRACT:"hPARP-3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PARP3, not a curated reading list.